On June 18, Russia had allowed clinical trials to Gamaleya National Research Center for Epidemiology and Microbiology on tow types of potential COVID-19 vaccine.
On Sunday, the Chief researcher Elena Smolyarchuk, the head of Gamaleya National Research Center for Epidemiology and Microbiology has confirmed the successful human trials of the potential Vaccine has ended.
The first vaccine is in the form of a solution, for intramuscular administration, tests were carried out at the Burdenko Military Hospital.
The Other Vaccine is in Powder form for preparation of a solution for intramuscular administration, carried out at Sechenov First Moscow State Medical University.
38 volunteers were involved in these trials at Sechenov University. For the first stage, a group of 18 volunteers was involved, and for the second stage further a group of 20 more. All the volunteers were expected to remain in an isolation for 28 days.
The tests showed the volunteers are immune to Corona Virus and doing well. The Chief researcher also confirmed that the volunteers will be discharged on July 15 and July 20.
However, no further information has been provided when this vaccine will enter in commercial production stage. According to the WHO, there are at least 21 vaccines that are now undergoing a key trial stage.
Russia has reported 719,449 positive cases and 11,188 deaths to date, with a global figure nearly 12.7 billion cases and 564,000 deaths according to Johns Hopkins University in the US.